Nuclear Medicine and Biology
Volume 35, Issue 8 , Pages 895-900 , November 2008

cis-4-[18F]-Fluoro-l-proline fails to detect peripheral tumors in humans

  • Gabriele Stoffels

      Affiliations

    • Institute of Neuroscience and Biophysics-Medicine, Research Centre Jülich, D-52425 Jülich, FRG
    • ,
  • Dirk Pauleit

      Affiliations

    • Institute of Neuroscience and Biophysics-Medicine, Research Centre Jülich, D-52425 Jülich, FRG
    • ,
  • Rainer Haas

      Affiliations

    • Department of Oncology, Hematology, and Clinical Immunology, Heinrich-Heine-University Düsseldorf, FRG
    • ,
  • Guido Kobbe

      Affiliations

    • Department of Oncology, Hematology, and Clinical Immunology, Heinrich-Heine-University Düsseldorf, FRG
    • ,
  • Dagmar Salber

      Affiliations

    • C. & O. Vogt Institute of Brain Research, Heinrich-Heine-University Düsseldorf, FRG
    • ,
  • Kurt Hamacher

      Affiliations

    • Institute of Neuroscience and Biophysics - Nuclear Chemistry, Research Centre Jülich, Jülich, FRG
    • ,
  • Heinz H. Coenen

      Affiliations

    • Institute of Neuroscience and Biophysics - Nuclear Chemistry, Research Centre Jülich, Jülich, FRG
    • ,
  • Karl-Josef Langen

      Affiliations

    • Institute of Neuroscience and Biophysics-Medicine, Research Centre Jülich, D-52425 Jülich, FRG
    • Corresponding Author InformationCorresponding author. Fax: +49 2461 612820.

Received 30 May 2008 ,Revised 11 August 2008 ,Accepted 26 August 2008.

References 

  1. Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY. 6-l-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med. 2008;49:573–586
  2. Salskov A, Tammisetti VS, Grierson J, Vesselle H. FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3′-deoxy-3′-[18F]fluorothymidine. Semin Nucl Med. 2007;37:429–439[Review]
  3. Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole. Semin Nucl Med. 2007;37:451–461
  4. Langen KJ, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D, et al. O-(2-[18F]fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol. 2006;33:287–294
  5. Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Müller HW, et al. O-(2-[18F]fluoroethyl)-l-tyrosine PET combined with magnetic resonance imaging improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128:678–687
  6. Pöpperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W, et al. FET-PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007;34:1933–1942
  7. Floeth FW, Pauleit D, Sabel M, Stoffels G, Reifenberger G, Riemenschneider MJ, et al. Prognostic value of O-(2-[18F]fluoroethyl)-l-tyrosine PET and MRI in low-grade glioma patients. J Nucl Med. 2007;48:519–527
  8. Hamacher K. Synthesis of n.c.a. cis- and trans-4-[18F]fluoro-l-proline, radiotracer for PET-investigation of disordered matrix protein synthesis. J Labelled Compd Radiopharm. 1999;42:1135–1142
  9. Wester HJ, Herz M, Senekowitsch-Schmidtke R, Schwaiger M, Stöcklin G, Hamacher K. Preclinical evaluation of 4-[18F]Fluoroprolines: diastereomeric effect on metabolism and uptake in mice. Nucl Med Biol. 1999;3:259–265
  10. Jones HA, Boobis AR, Hamacher K, Coenen HH, Clark JC. PET imaging of pulmonary fibrosis. J Nucl Med. 2003;44:483–484
  11. Wallace WE, Gupta NC, Hubbs AF, Mazza SM, Bishop HA, Keane MJ, et al. cis-4-[(18)F]fluoro-l-proline PET imaging of pulmonary fibrosis in a rabbit model. J Nucl Med. 2002;43:413–420
  12. Zimny M, Klosterhalfen B, Conze J, Hamacher K, Fehler S, Schumpelick V, et al. Uptake of cis-4-[18 F]fluoro-l-proline in scar formation: a marker of collagen synthesis?. Nucl Med Commun. 2002;23:695–698
  13. Langen KJ, Jarosch M, Hamacher K, Mühlensiepen H, Weber F, Floeth F, et al. Imaging of gliomas with cis-4-[18F]fluoro-l-proline. Nucl Med Biol. 2004;31:67–75
  14. Langen KJ, Börner AR, Müller-Mattheis V, Hamacher K, Herzog H, Ackermann R, et al. Uptake of cis-4-[18F]fluoro-l-proline in urologic tumors. J Nucl Med. 2001;42:752–754
  15. Langen KJ, Mühlensiepen H, Schmieder S, Hamacher K, Broer S, Börner AR, et al. Transport of cis- and trans-4-[(18)F]fluoro-l-proline in F98 glioma cells. Nucl Med Biol. 2002;29:685–692
  16. Saier MH, Daniels GA, Boerner P, Lin J. Neutral amino acid transport systems in animal cells: potential targets of oncogene action and regulators of cellular growth. J Membr Biol. 1988;104:1–20
  17. Sutinen E, Jyrkkiö S, Grönroos T, Haaparanta M, Lehikoinen P, Någren K. Biodistribution of [11C] methylaminoisobutyric acid, a tracer for PET studies on system A amino acid transport in vivo. Eur J Nucl Med. 2001;28:847–854
  18. Sutinen E, Jyrkkiö S, Alanen K, Någren K, Minn H. Uptake of [N-methyl-11C]alpha-methylaminoisobutyric acid in untreated head and neck cancer studied by PET. Eur J Nucl Med Mol Imaging. 2003;30:72–77
  19. Hamacher K, Coenen HH, Stöcklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235–238
  20. Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92:50–55
  21. Börner AR, Langen KJ, Herzog H, Hamacher K, Müller-Mattheis V, Schmitz T, et al. Whole-body kinetics and dosimetry of cis-4-[(18)F]fluoro-l-proline. Nucl Med Biol. 2001;28:287–292
  22. Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M, et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-l-tyrosine for tumor imaging. J Nucl Med. 1999;40:205–212
  23. Pauleit D, Stoffels G, Schaden W, Hamacher K, Bauer D, Tellmann L, et al. PET with O-(2-[18F]fluoroethyl)-l-tyrosine (FET) in peripheral tumors: first clinical results. J Nucl Med. 2005;46:411–416
  24. Langen KJ, Hamacher K, Bauer D, Bröer S, Pauleit D, Herzog H, et al. Preferred stereoselective transport of the d-Isomer of cis-4-[18F]fluoro-proline at the blood-brain barrier. J Cereb Blood Flow Metab. 2005;25:607–616
  25. Langen KJ, Salber D, Hamacher K, Stoffels G, Reifenberger G, Pauleit D, et al. Detection of secondary thalamic degeneration after cortical infarction using cis-4-[18F]fluoro-d-proline. J Nucl Med. 2007;48:1482–1491

PII: S0969-8051(08)00178-9

doi: 10.1016/j.nucmedbio.2008.08.003

Nuclear Medicine and Biology
Volume 35, Issue 8 , Pages 895-900 , November 2008

Article Tools

* Image Usage & Resolution